(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.69%.
Tempest Therapeutics's earnings in 2026 is -$43,098,000.On average, 3 Wall Street analysts forecast TPST's earnings for 2026 to be -$20,238,203, with the lowest TPST earnings forecast at -$19,444,548, and the highest TPST earnings forecast at -$20,833,445. On average, 3 Wall Street analysts forecast TPST's earnings for 2027 to be -$18,274,796, with the lowest TPST earnings forecast at -$17,558,137, and the highest TPST earnings forecast at -$18,812,290.
In 2028, TPST is forecast to generate -$13,441,792 in earnings, with the lowest earnings forecast at -$12,914,663 and the highest earnings forecast at -$13,837,139.